Newron Pharmaceuticals S.p.A. (FRA:NP5)
21.80
+0.05 (0.23%)
At close: Jan 30, 2026
Newron Pharmaceuticals Revenue
Newron Pharmaceuticals had revenue of 11.90M EUR in the half year ending June 30, 2025, with 116.56% growth. This brings the company's revenue in the last twelve months to 59.88M, up 759.12% year-over-year. In the year 2024, Newron Pharmaceuticals had annual revenue of 51.39M with 467.41% growth.
Revenue (ttm)
59.88M
Revenue Growth
+759.12%
P/S Ratio
7.11
Revenue / Employee
2.72M
Employees
22
Market Cap
425.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.39M | 42.33M | 467.41% |
| Dec 31, 2023 | 9.06M | 2.96M | 48.62% |
| Dec 31, 2022 | 6.09M | 332.00K | 5.76% |
| Dec 31, 2021 | 5.76M | 504.00K | 9.59% |
| Dec 31, 2020 | 5.26M | -1.78M | -25.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| SIMONA Aktiengesellschaft | 586.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| centrotherm international AG | 288.81M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Novabase S.G.P.S. | 130.35M |
| Wild Bunch AG | 68.86M |